147 related articles for article (PubMed ID: 28731044)
1. Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients.
Rosenbaum BE; Schafer CN; Han SW; Osman I; Zhong H; Brinster N
Mod Pathol; 2017 Oct; 30(10):1402-1410. PubMed ID: 28731044
[TBL] [Abstract][Full Text] [Related]
2. Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.
Hale CS; Qian M; Ma MW; Scanlon P; Berman RS; Shapiro RL; Pavlick AC; Shao Y; Polsky D; Osman I; Darvishian F
Am J Surg Pathol; 2013 Jun; 37(6):882-9. PubMed ID: 23629443
[TBL] [Abstract][Full Text] [Related]
3. Automated digital volume measurement of melanoma metastases in sentinel nodes predicts disease recurrence and survival.
Riber-Hansen R; Nyengaard JR; Hamilton-Dutoit SJ; Sjoegren P; Steiniche T
Histopathology; 2011 Sep; 59(3):433-40. PubMed ID: 22034883
[TBL] [Abstract][Full Text] [Related]
4. Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.
Harcharik S; Bernardo S; Moskalenko M; Pan M; Sivendran M; Bell H; Hall LD; Castillo-Martín M; Fox K; Cordon-Cardo C; Chang R; Sivendran S; Phelps RG; Saenger Y
J Am Acad Dermatol; 2014 Jun; 70(6):1036-44. PubMed ID: 24698703
[TBL] [Abstract][Full Text] [Related]
5. Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Nielsen PS; Riber-Hansen R; Jensen TO; Schmidt H; Steiniche T
Mod Pathol; 2013 Mar; 26(3):404-13. PubMed ID: 23174936
[TBL] [Abstract][Full Text] [Related]
6. A high proliferative index of recurrent melanoma is associated with worse survival.
Tu TJ; Ma MW; Monni S; Rose AE; Yee H; Darvishian F; Polsky D; Berman RS; Shapiro RL; Pavlick AC; Mazumdar M; Osman I
Oncology; 2011; 80(3-4):181-7. PubMed ID: 21701232
[TBL] [Abstract][Full Text] [Related]
7. Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma.
Chou M; Illa-Bochaca I; Minxi B; Darvishian F; Johannet P; Moran U; Shapiro RL; Berman RS; Osman I; Jour G; Zhong H
Mod Pathol; 2021 Mar; 34(3):562-571. PubMed ID: 33005020
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
9. Sarcopenia as a prognostic factor among patients with stage III melanoma.
Sabel MS; Lee J; Cai S; Englesbe MJ; Holcombe S; Wang S
Ann Surg Oncol; 2011 Dec; 18(13):3579-85. PubMed ID: 21822551
[TBL] [Abstract][Full Text] [Related]
10. Patterns of recurrence and retreatment outcomes among clinical stage I and II head and neck melanoma patients.
Namin AW; Cornell GE; Thombs LA; Zitsch RP
Head Neck; 2019 May; 41(5):1304-1311. PubMed ID: 30629324
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.
Corrie PG; Marshall A; Dunn JA; Middleton MR; Nathan PD; Gore M; Davidson N; Nicholson S; Kelly CG; Marples M; Danson SJ; Marshall E; Houston SJ; Board RE; Waterston AM; Nobes JP; Harries M; Kumar S; Young G; Lorigan P
Lancet Oncol; 2014 May; 15(6):620-30. PubMed ID: 24745696
[TBL] [Abstract][Full Text] [Related]
12. Survival and Surgical Outcomes for Pediatric Head and Neck Melanoma.
Richards MK; Czechowicz J; Goldin AB; Gow KW; Doski J; Goldfarb M; Nuchtern J; Langer M; Beierle EA; Vasudevan S; Gupta D; Parikh SR
JAMA Otolaryngol Head Neck Surg; 2017 Jan; 143(1):34-40. PubMed ID: 27607058
[TBL] [Abstract][Full Text] [Related]
13. Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics.
Luen S; Wong SW; Mar V; Kelly JW; McLean C; McArthur GA; Haydon A
Am J Clin Oncol; 2018 Jan; 41(1):90-94. PubMed ID: 26325493
[TBL] [Abstract][Full Text] [Related]
14. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
15. Recurrent malignant melanoma: the identification of prognostic factors to predict survival.
Reintgen DS; Cox C; Slingluff CL; Seigler HF
Ann Plast Surg; 1992 Jan; 28(1):45-9. PubMed ID: 1642405
[TBL] [Abstract][Full Text] [Related]
16. Conditional Survival-Based "Abbreviated" Routine Cancer Surveillance for Pathologic Stage IB Melanoma.
Kukar M; Gabriel E; May R; Cho E; Lichtenthal M; Groman A; Skitzki J; Francescutti V; Kane JM
Am Surg; 2017 Nov; 83(11):1256-1262. PubMed ID: 29183528
[TBL] [Abstract][Full Text] [Related]
17. Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.
Varey AHR; Goumas C; Hong AM; Mann GJ; Fogarty GB; Stretch JR; Saw RPM; Spillane AJ; Shannon KF; Lee KJ; Quinn MJ; Thompson JF; Scolyer RA
Mod Pathol; 2017 Nov; 30(11):1538-1550. PubMed ID: 28731051
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.
Burmeister BH; Henderson MA; Ainslie J; Fisher R; Di Iulio J; Smithers BM; Hong A; Shannon K; Scolyer RA; Carruthers S; Coventry BJ; Babington S; Duprat J; Hoekstra HJ; Thompson JF
Lancet Oncol; 2012 Jun; 13(6):589-97. PubMed ID: 22575589
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and patterns of recurrence after sentinel lymph node biopsy for thin melanoma.
Kim D; Chu S; Khan AU; Compres EV; Zhang H; Gerami P; Wayne JD
Arch Dermatol Res; 2022 Apr; 314(3):285-292. PubMed ID: 33884478
[TBL] [Abstract][Full Text] [Related]
20. A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease.
Day CL; Sober AJ; Kopf AW; Lew RA; Mihm MC; Hennessey P; Golomb FM; Harris MN; Gumport SL; Raker JW; Malt RA; Cosimi AB; Wood WC; Roses DF; Gorstein F; Postel A; Grier WR; Mintzis MN; Fitzpatrick TB
Ann Surg; 1981 Apr; 193(4):436-40. PubMed ID: 7212806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
